#USA #Berwyn #Nordic Pharma #Dry Eye #LACRIFILL®

Inclusion of LACRIFILL® Canalicular Gel in the Latest DEWS III Report

Nordic Pharma, Inc., which is part of the Nordic Group B.V., recently announced that their innovative canalicular gel, LACRIFILL®, has been included in the new management and therapy report from the Dry Eye Workshop (DEWS) III produced by the Tear Film and Ocular Surface Society (TFOS). This acknowledgement highlights the gel’s growing significance in treating dry eye symptoms and provides practitioners with valuable insights into the latest therapeutic approaches.

DEWS III Report Overview

The DEWS III report, featured in the June 2025 edition of the American Journal of Ophthalmology, cites two pivotal studies pertaining to the use of LACRIFILL®. Specifically, the inclusion falls under Section 6.2.4, which discusses “New Connector Designs and Other Technologies”. The first study showed notable improvements in corneal staining and Schirmer test scores, indicating enhanced ocular comfort three months post-application of the gel. The second study placed LACRIFILL® in comparison with an existing commercial hydrogel connector, concluding that the patented hyaluronic acid (HA) gel is not only safe and well-tolerated but that its efficacy in alleviating dry eye symptoms remains statistically significant for up to six months.

Presentation at Women in Ophthalmology Symposium

The research surrounding LACRIFILL® will gain further visibility as it is presented at the Women in Ophthalmology Summer Symposium (WIO), taking place from August 7 to 10. Monica Patel and colleagues will present findings from their research titled, “Assessment of Lacrimal Connector Insertion for Dry Eye Relief through Patient Self-Evaluation and OSDI Surveys.” In this study involving 117 participants, an impressive 66.25% reported at least a 50% reduction in symptoms one month after applying LACRIFILL®, with many experiencing up to 90-100% improvement, particularly in terms of burning and gritty sensations.

Dr. Patel emphasizes the coherence of subjective improvements alongside OSDI scores, asserting that this validates self-reporting as an effective tool for evaluating new treatments. Such insights can immensely assist healthcare professionals in deciding on appropriate therapeutic paths for their patients.

Expert Opinions on LACRIFILL®

In discussing the results, Dr. Jai Parekh, a leading figure at Eye Care U.S., confirmed the efficacy of LACRIFILL® for alleviating symptoms of dry eye. Both the self-reported improvements and recorded OSDI scores provide compelling evidence of the gel’s benefits across diverse patient demographics, including those with underlying conditions such as diabetes or thyroid diseases with glaucoma.

Additional Case Studies Validate Efficacy

Further supporting the claims regarding LACRIFILL®, two recent case studies illustrate its effectiveness in clinical settings. One case presented by Dr. Jennifer Loh in Cataract Refractive Surgery Today involved a patient experiencing blurred vision after cataract surgery. Following unsuccessful treatments with steroids, artificial tears, and compresses, the introduction of LACRIFILL® helped enhance tear film stability, yielding significant improvements in visual acuity.

Another study documented by Dr. Selina McGee in Modern Optometry involved a patient suffering from unmanageable ocular surface disease treated with an immunomodulator. The introduction of LACRIFILL® led to substantial reductions in scalp scores from 10/28 to 5/18 and a notable resolution in corneal staining, demonstrating the gel’s multifaceted benefits.

Conclusion

As Nordic Pharma, Inc. continues to partner with prominent biopharmaceutical companies globally, products like LACRIFILL® underscore the firm’s commitment to advancing ocular health. Interested parties can visit lacrifill.com for inquiries about the gel’s availability.

About Nordic Group B.V.

Nordic Group B.V. is a mid-sized international pharmaceutical company, focusing on specialized product development and marketing. The company strategically boosts its portfolio through targeted product development and acquisitions, particularly in fields such as ocular health, rheumatology, and women's health. With a solid presence throughout Europe, Nordic Group has recently expanded its global outreach significantly.

About Nordic Pharma, Inc.

As a subsidiary of Nordic Group B.V., Nordic Pharma, Inc. collaborates with established global biopharmaceutical companies to leverage advanced technologies and bring innovative healthcare solutions to the market.

Forward-Looking Statements

This press release contains forward-looking statements that reflect Nordic Group's current views and expectations regarding future events. There are inherent risks and uncertainties that may cause actual results to differ from those projected. Nordic Group does not assume any obligation to update these statements publicly.

Contact

For further inquiries, please contact:

• - Kate Popova: Project and Contract Manager, Tel: 610-285-1699, Email: [email protected]
• - Gail Feerrar: Sales and Marketing Director, Tel: 610-285-7152, Email: [email protected]